Seven Eight Capital, LP Biocryst Pharmaceuticals Inc Transaction History

Seven Eight Capital, LP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 12, 2024	BUY	$4.13 - $6.79 $654,018 - $1.08 Million	158,358 Added 1407.13%	169,612 $1.05 Million
Q1 2024 May 13, 2024	BUY	$4.89 - $7.65 $55,032 - $86,093	11,254 New	11,254 $57,000
Q3 2022 Nov 10, 2022	BUY	$10.79 - $14.81 $219,360 - $301,087	20,330 New	20,330 $256,000
Q4 2021 Feb 14, 2022	SELL	$11.18 - $15.46 $560,475 - $775,040	-50,132 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$14.21 - $17.65 $95,718 - $118,890	6,736 Added 15.52%	50,132 $720,000
Q2 2021 Aug 13, 2021	BUY	$9.5 - $17.24 $110,162 - $199,915	11,596 Added 36.47%	43,396 $686,000
Q4 2020 Feb 09, 2021	BUY	$3.37 - $8.61 $107,166 - $273,798	31,800 New	31,800 $237,000

278

171M

625K

739K

Ticker BCRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,944,992
Market Cap $1.42B
Description
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...

Get notified when there are updates to the investment portfolio of Seven Eight Capital, LP, based on Form 13F filings with the SEC.

Stay updated on Seven Eight Capital, LP with notifications on news.